AstraZeneca (NASDAQ:AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of PTEN-deficient ...
The trial compared the regimen versus the standard-of-care Zytiga and ADT in patients with PTEN-deficient de novo metastatic ...
Patients with PTEN-deficient prostate cancer showed improvement in progression-free survival on Truqap plus standard therapy compared to standard therapy alone.
HealthDay on MSN6d
Understanding the Stages of Breast Cancer: 0, 1, 2, 3 & 4A diagnosis of breast cancer comes with many tough questions, but one of the biggest is what stage your cancer is. Millions ...
13don MSN
Bioluminescence is the natural chemical process of light creation in some living creatures that makes fireflies flicker and ...
The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...
IceCure Medical Ltd. recently announced the FDA Medical Device Advisory Committee Panel’s favorable recommendation (voti ...
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday positive high-level results from CAPItello-281 Phase III trial of ...
For Sortilin and TfR, the team used Rossetta de novo binder design software to designed synthetic ... They also targeted PD-L1— an immune checkpoint protein that helps cancer cells evade immune ...
Years of developing cancer therapies targeted to specific molecular ... receive the Smoothened inhibitor 2 (Fig. 1). Figure 1: A de novo tumor model mimics the growth patterns of the human tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback